Comparative Pharmacology
Head-to-head clinical analysis: AKOVAZ versus BENSULFOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AKOVAZ versus BENSULFOID.
AKOVAZ vs BENSULFOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Akovaz (ephedrine sulfate) is a sympathomimetic amine that directly stimulates alpha- and beta-adrenergic receptors, and indirectly by releasing norepinephrine from presynaptic terminals, leading to increased heart rate and contractility, and vasoconstriction.
Unknown; may inhibit Na+/K+-ATPase pump and increase renal sodium excretion
5 mg intravenously once daily.
Bensulfoid: not a recognized drug. No data available.
None Documented
None Documented
Terminal elimination half-life: 3-4 hours, prolonged in renal impairment (up to 8-12 hours in severe CKD).
Terminal elimination half-life: 12-18 hours in adults with normal renal function; prolonged to 24-48 hours in moderate renal impairment (CrCl 30-50 mL/min).
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites and unchanged drug.
Renal excretion of unchanged drug: 70-80%; biliary/fecal: 15-20%; metabolic inactivation accounts for the remainder.
Category C
Category C
Topical Antibiotic
Topical Antibiotic